Ibrutinib for B cell malignancies

Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Novero, Aileen, Ravella, Pavan M, Chen, Yamei, Dous, George, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913970/
https://www.ncbi.nlm.nih.gov/pubmed/24472371
http://dx.doi.org/10.1186/2162-3619-3-4
_version_ 1782302318218182656
author Novero, Aileen
Ravella, Pavan M
Chen, Yamei
Dous, George
Liu, Delong
author_facet Novero, Aileen
Ravella, Pavan M
Chen, Yamei
Dous, George
Liu, Delong
author_sort Novero, Aileen
collection PubMed
description Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765), a potent inhibitor of BTK induces impressive responses in B-cell malignancies through irreversible bond with cysteine-481 in the active site of BTK (TH/SH1 domain) and inhibits BTK phosphorylation on Tyr(223). This review discussed in details the role of BTK in B-cell signaling, molecular interactions between B cell lymphoma/leukemia cells and their microenvironment. Clinical trials of the novel BTK inhibitor, ibrutinib (PCI-32765), in B cell malignancies were summarized.
format Online
Article
Text
id pubmed-3913970
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39139702014-02-06 Ibrutinib for B cell malignancies Novero, Aileen Ravella, Pavan M Chen, Yamei Dous, George Liu, Delong Exp Hematol Oncol Review Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765), a potent inhibitor of BTK induces impressive responses in B-cell malignancies through irreversible bond with cysteine-481 in the active site of BTK (TH/SH1 domain) and inhibits BTK phosphorylation on Tyr(223). This review discussed in details the role of BTK in B-cell signaling, molecular interactions between B cell lymphoma/leukemia cells and their microenvironment. Clinical trials of the novel BTK inhibitor, ibrutinib (PCI-32765), in B cell malignancies were summarized. BioMed Central 2014-01-28 /pmc/articles/PMC3913970/ /pubmed/24472371 http://dx.doi.org/10.1186/2162-3619-3-4 Text en Copyright © 2014 Novero et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Novero, Aileen
Ravella, Pavan M
Chen, Yamei
Dous, George
Liu, Delong
Ibrutinib for B cell malignancies
title Ibrutinib for B cell malignancies
title_full Ibrutinib for B cell malignancies
title_fullStr Ibrutinib for B cell malignancies
title_full_unstemmed Ibrutinib for B cell malignancies
title_short Ibrutinib for B cell malignancies
title_sort ibrutinib for b cell malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913970/
https://www.ncbi.nlm.nih.gov/pubmed/24472371
http://dx.doi.org/10.1186/2162-3619-3-4
work_keys_str_mv AT noveroaileen ibrutinibforbcellmalignancies
AT ravellapavanm ibrutinibforbcellmalignancies
AT chenyamei ibrutinibforbcellmalignancies
AT dousgeorge ibrutinibforbcellmalignancies
AT liudelong ibrutinibforbcellmalignancies

Ejemplares similares